v3.26.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Total revenue $ 41,568 $ 38,108 $ 76,022 $ 70,083
Total cost of revenues 20,345 20,350 38,645 36,587
Gross profit 21,223 17,758 37,377 33,496
Operating expenses:        
Sales and marketing 9,984 11,868 20,721 23,867
General and administrative 11,404 12,150 24,452 25,287
Research and development 1,336 1,798 2,700 3,414
Total operating expenses 22,724 25,816 47,873 52,568
Loss from operations (1,501) (8,058) (10,496) (19,072)
Other (income) expense:        
Interest expense 2,125 1,969 4,391 3,891
Loss on extinguishment of debt     539  
Other income, net (162) (188) (1,182) (435)
Net loss (3,464) (9,839) (14,244) (22,528)
Less: Net gain (loss) attributable to non-controlling interest (25) 281 (15) 267
Net loss attributable to Neuronetics stockholders $ (3,439) $ (10,120) $ (14,229) $ (22,795)
Net loss per share of common stock outstanding, basic attributable to Neuronetics stockholders (in dollars per share) $ (0.05) $ (0.15) $ (0.2) $ (0.36)
Net loss per share of common stock outstanding, diluted attributable to Neuronetics stockholders (in dollars per share) $ (0.05) $ (0.15) $ (0.2) $ (0.36)
Weighted average common shares outstanding, basic (in shares) 73,129 66,180 71,369 63,835
Weighted average common shares outstanding, diluted (in shares) 73,129 66,180 71,369 63,835
NeuroStar        
Total revenue $ 14,677 $ 15,084 $ 27,602 $ 28,400
Total cost of revenues 3,312 4,311 6,170 7,461
Greenbrook        
Total revenue 26,891 23,024 48,420 41,683
Total cost of revenues $ 17,033 $ 16,039 $ 32,475 $ 29,126